CONSYGEN INC
10QSB, 2001-01-12
PREPACKAGED SOFTWARE
Previous: CONSYGEN INC, 10QSB/A, 2001-01-12
Next: DEAN C H & ASSOCIATES INC, 13F-HR, 2001-01-12



                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

            Quarterly report pursuant to Section 13 or 15 (d) of the
                        Securities Exchange Act of 1934

                For the quarterly period ended November 30, 2000

                          Commission File Number: 17598

                                 CONSYGEN, INC.
             ------------------------------------------------------
             (Exact name of Registrant as specified in its charter)

                Texas                                            76-0260145
  -------------------------------                             ----------------
  (State or other jurisdiction of                             (I.R.S. Employer
   incorporation or organization)                            Identification No.)


 125 South 52nd Street, Tempe, Arizona                             85281
----------------------------------------                         ----------
(Address of principal executive offices)                         (Zip Code)

                                 (480) 394-9100
              ----------------------------------------------------
              (Registrant's telephone number, including area code)

Indicate  by check  mark  whether  the  registrant:  (1) has filed  all  reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant  was required to file such  reports) and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

   35,500,954 shares of Common Stock, $.003 par value, as of January 8, 2001.
<PAGE>
                                 CONSYGEN, INC.

                                      INDEX

PART I. FINANCIAL INFORMATION:

   Item 1. Financial Statements.

           Consolidated Balance Sheet, November 30, 2000                     2

           Consolidated Statements of Operations - Six
           Months Ended November 30, 2000 and November 30, 1999              3

           Consolidated Statements of Cash Flows - Six
           Months Ended November 30, 2000 and November 30, 1999              4

           Notes to Consolidated Financial Statements                        5

   Item 2. Management's Discussion and Analysis of Financial
           Condition and Results of Operations                               5

PART II. OTHER INFORMATION

   Item 5. Other Information                                                10

   Item 6. Exhibits and Reports on Form 8-K.                                10

SIGNATURES                                                                  11

                  CAUTION REGARDING FORWARD-LOOKING STATEMENTS

     CERTAIN STATEMENTS  CONTAINED IN THIS REPORT AND IN DOCUMENTS  INCORPORATED
BY REFERENCE HEREIN CONSTITUTE  "FORWARD-LOOKING  STATEMENTS" WITHIN THE MEANING
OF SECTION 27A OF THE  SECURITIES  ACT OF 1933 AND SECTION 21E OF THE SECURITIES
EXCHANGE ACT OF 1934.  FOR THIS  PURPOSE,  ANY  STATEMENTS  CONTAINED  HEREIN OR
INCORPORATED BY REFERENCE  HEREIN THAT ARE NOT STATEMENTS OF HISTORICAL FACT MAY
BE DEEMED TO BE FORWARD-LOOKING STATEMENTS.  WITHOUT LIMITING THE FOREGOING, THE
WORDS "BELIEVES," "PLANS,"  "ANTICIPATES,"  "EXPECTS,"  "ESTIMATES," AND SIMILAR
EXPRESSIONS ARE INTENDED TO IDENTIFY  FORWARD-LOOKING  STATEMENTS.  ALTHOUGH THE
COMPANY BELIEVES THAT THE ASSUMPTIONS ON WHICH SUCH  FORWARD-LOOKING  STATEMENTS
ARE BASED ARE REASONABLE,  THERE CAN BE NO ASSURANCE THAT SUCH  ASSUMPTIONS WILL
PROVE TO BE ACCURATE,  AND ACTUAL  RESULTS  COULD DIFFER  MATERIALLY  FROM THOSE
DISCUSSED  IN  THE  FORWARD-LOOKING  STATEMENTS.   FACTORS  THAT  MAY  CAUSE  OR
CONTRIBUTE TO SUCH DIFFERENCES  INCLUDE, BUT ARE NOT LIMITED TO, THOSE SET FORTH
UNDER THE CAPTION  "MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS" AND ELSEWHERE IN THIS REPORT.
<PAGE>
                         PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

                                 CONSYGEN, INC.
                           CONSOLIDATED BALANCE SHEET

                                                                   November 30,
                                                                       2000
                                     ASSETS                        ------------
Current Assets:
  Cash and Cash Equivalents                                        $         --
  Accounts Receivable                                                    35,275
  Inventory                                                             216,453
  Prepaid Expenses                                                      146,177
  Other Current Assets                                                      708
                                                                   ------------
     Total Current Assets                                               398,613
                                                                   ------------
Property and Equipment - Net                                          1,505,818
                                                                   ------------
Other Assets:
  Debt Issuance Expense                                                  65,275
  Notes receivable                                                       72,725
  Other Assets                                                           56,708
                                                                   ------------
     Total Other Assets                                                 194,709
                                                                   ------------
     Total Assets                                                  $  2,099,140
                                                                   ============

                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities:
  Accounts Payable                                                 $    552,599
  Notes Payable                                                       1,034,484
  Capital Lease - Current portion                                        28,289
  Accrued Liabilities                                                 1,318,342
                                                                   ------------
     Total Current Liabilities                                        2,933,713

Convertible Debentures                                                  656,751
Capital Lease - Long Term Portion                                        66,408
Mortgage - Long Term                                                    529,154
Long-Term Debt                                                          634,140
                                                                   ------------

     Total Liabilities                                                4,820,167
                                                                   ------------
Commitments & Contingencies

Stockholders' Equity :
  Common Stock, $.003 par Value, Authorized 40,000,000 Shares,
   issued and outstanding 35,500,954 Shares at November 30, 2000        102,593
  Additional Paid-in Capital                                         34,098,336
  Accumulated Deficit                                               (36,506,232)
  Treasury Stock, at cost ( 90,000 shares)                             (415,725)
                                                                   ------------
     Total Stockholders' Equity                                      (2,721,027)
                                                                   ------------

     Total Liabilities and Stockholders' Equity                    $  2,099,140
                                                                   ============

The accompanying notes are an integral part of the financial statements.

                                       2
<PAGE>
                                 CONSYGEN, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                     For the Three Months             For the Six Months
                                                        Ended November                  Ended November
                                                 ----------------------------    ----------------------------
                                                     2000            1999            2000             1999
                                                 ------------    ------------    ------------    ------------
<S>                                              <C>             <C>             <C>             <C>
Counterfeit Cop Revenue                          $     35,810    $     30,412    $    779,439    $     74,915
Software Services Revenue                                  --          35,023              --         108,388
                                                 ------------    ------------    ------------    ------------
Revenues                                               35,810          65,435         779,439         183,303
                                                 ------------    ------------    ------------    ------------
Costs and Expenses:
  Cost of Sales - Cop                                  12,757           7,270         212,030          16,513
  Cost of Sales - Software Services                        --          65,880              --         270,563
  Software Development                                415,227         190,206         710,767         315,381
  Selling, General and Administrative Expenses        778,650         598,325       1,691,948       1,382,260
  Interest Expense                                    276,119         136,113         434,105         233,127
  Depreciation and Amortization                        40,968          65,992          82,829         125,002
                                                 ------------    ------------    ------------    ------------

     Total Costs and Expenses                       1,523,721       1,063,786       3,131,679       2,342,846
                                                 ------------    ------------    ------------    ------------

Loss from Operations                               (1,487,911)       (998,351)     (2,352,240)     (2,159,543)

Interest Income                                            --              --              --           5,755
Other Income                                               --              --             275          27,493
Other Expenses                                             --          (2,500)             --        (289,958)
                                                 ------------    ------------    ------------    ------------
Net Loss                                         $ (1,487,911)   $ (1,000,851)   $ (2,351,965)   $ (2,416,253)
                                                 ============    ============    ============    ============

Weighted Average Common Shares Outstanding         32,881,687      15,427,301      29,069,838      15,427,301
                                                 ============    ============    ============    ============

Net Loss per Common Share                        $      (0.05)   $      (0.06)   $      (0.08)   $      (0.16)
                                                 ============    ============    ============    ============
</TABLE>

The accompanying notes are an integral part of the financial statements.

                                       3
<PAGE>
                                 CONSYGEN, INC.
                      CONSOLIDATED STATEMENT OF CASH FLOWS
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                       For the Six Months Ended
                                                                              November 30,
                                                                    -----------------------------
                                                                        2000              1999
                                                                    -----------       -----------
<S>                                                                 <C>               <C>
Cash Flows from Operating Activities:
 Net Loss                                                           $(2,351,965)      $(2,416,254)
 Adjustments to Reconcile Net Loss to
  Net Cash (Used) by Operating Activities:
  Depreciation and amortization                                          82,829           126,577
  Write-off of investment in technology                                                   230,000
  Amortization of deferred financing costs                               58,189            93,529
  Changes in Operating Assets and Liabilities:
   Accounts Receivable                                                   14,187            (5,809)
   Inventories                                                          195,885          (264,968)
   Prepaid Expenses and Other Assets                                    144,591            (9,616)
   Accounts Payable                                                     217,122           221,722
   Accrued Liabilities                                                  278,041           378,723
                                                                    -----------       -----------
        Net Cash (Used) by Operating Activities                      (1,361,121)       (1,646,096)
                                                                    -----------       -----------
Cash Flows from Investing Activities:
 Utilization of certificate of deposit for inventory purchases               --           445,669
 Purchase of technology                                                      --          (230,000)
 Advances on note receivable                                            (34,200)
 Purchases of Furniture and Equipment                                   (22,165)          (68,049)
 Investment in joint venture                                            (20,000)
                                                                    -----------       -----------
        Net Cash (Used) by Investing Activities                         (76,365)          147,620
                                                                    -----------       -----------
Cash Flows from Financing Activities:
 Proceeds from Sale of Common Stock                                     867,184            14,941
 Payments of principal on loans                                         (12,355)           (6,223)
 Bank overdraft                                                         102,111
 Proceeds of Loans payable -- Related Parties                           461,694           402,450
 Proceeds on other notes payable                                         58,897           420,868
 Purchase of treasury stock                                             (15,725)
 Payments of principal on capital lease obligations                     (27,925)          (17,670)
 Payments for financing costs                                                --           (40,871)
                                                                    -----------       -----------
        Net Cash Provided by Financing Activities                     1,433,881           773,495
                                                                    -----------       -----------
Net Decrease in Cash and Cash Equivalents                                (3,605)         (724,981)

Cash and Cash Equivalents -- Beginning of Period                          3,605           739,308
                                                                    -----------       -----------

Cash and Cash Equivalents -- End of Period                                    0       $    14,327
                                                                    ===========       ===========
Supplemental Cash Flow Information:
 Cash Paid for Interest                                             $    76,817       $    49,470
                                                                    ===========       ===========
Non-Cash Financing and Investing Activities:
 Issuance of Common Stock as Loan Incentive                         $        --       $    20,839
                                                                    ===========       ===========
 Conversion of debt to common stock                                 $   651,190       $        --
                                                                    ===========       ===========
  Issuance of common stock for prepaid professional fees            $   287,505       $        --
                                                                    ===========       ===========
  Issuance of common stock for equipment                            $   283,500       $        --
                                                                    ===========       ===========
  Equipment acquired under capital lease                            $    52,054       $        --
                                                                    ===========       ===========

The accompanying notes are an integral part of the financial statements.

                                       4
<PAGE>
                                 CONSYGEN, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                          November 30, 2000 (Unaudited)


NOTE 1 - BASIS OF PRESENTATION

     The  consolidated  financial  statements  include the accounts of ConSyGen,
Inc., a Texas corporation  ("ConSyGen-Texas")  and its wholly-owned  subsidiary,
ConSyGen,  Inc.,  an  Arizona  corporation   ("ConSyGen-Arizona").   Significant
intercompany accounts and transactions have been eliminated.

     ConSyGen-Texas  and  its  wholly-owned   subsidiary   ConSyGen-Arizona  are
hereafter collectively referred to as the "Company."

     In the opinion of the  Company,  the  accompanying  unaudited  consolidated
financial   statements  reflect  all  adjustments  (which  include  only  normal
recurring adjustments) necessary to present fairly the results of operations and
cash flows for the periods presented.

     Results of operations for interim periods are not necessarily indicative of
the  results of  operations  for a full year due to  external  factors  that are
beyond the control of the Company.

NOTE 2 - STOCKHOLDERS' EQUITY (DEFICIT)

     STOCK OPTIONS

     The Company issued stock options to employees that were later repriced.  In
accordance with APB No. 25, these options are now classified as variable awards.
On the basis of the price of the  Company's  common  stock at November 30, 2000,
there was no decrease in the intrinsic  value of those options was recognized as
other income in the three months ended November 30, 2000. The Company intends to
continue to compensate employees with stock options.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

     The following  discussion and analysis  should be read in conjunction  with
the Company's  Consolidated Financial Statements and the Notes thereto appearing
elsewhere  in  the  Report.   The  Company  and  its  wholly-owned   subsidiary,
ConSyGen-Arizona, are herein collectively referred to as the "Company."

                                       5
<PAGE>
OVERVIEW

     Historically,  we have  developed  pre-packaged  software  and  proprietary
products and services.  However, we have recently moved our specific emphasis to
identifying developing  software-related business opportunities and technologies
and  providing   timely  and  effective   software-based   solutions  for  these
opportunities,  while still maintaining our traditional emphasis on high-quality
proprietary products and services.

     We  are  marketing  the  COUNTERFEIT  COP  through  our  Business  Products
Division.  We have entered into distribution  agreements with third parties with
national  domestic  distribution  networks,  and we have  incorporated  ConSyGen
s.r.o. in the Czech Republic to market the product in Europe.  CE  certification
has been secured,  and we began shipping units to Europe during the quarter.  We
intend  to  continue  the  active   marketing  of  this  product  through  these
distribution channels and others that we expect to create in the future.

     We have  completed the first phase of the  development  of the BIZPAY SUITE
software - a new  "e-commerce"  product.  We have  incorporated  a new  company,
BizPay International,  to hold our interests in various BizPay businesses around
the world. We have established a joint venture with an Australian  partner,  and
have signed several  Memorandums of Understanding  (MOU) with strategic partners
to  introduce  the product in Europe,  and several  other  locations  around the
world.  Additionally,  we have entered into a definitive  partnership  agreement
with  Cardservice  International,  a merchant  processor,  to develop the BizPay
business in the United  States.  These  transactions  are subject to  definitive
agreements.  During the  quarter,  we  demonstrated  the  software  for  several
potential  domestic and  international  partners,  and have begun  modifying the
software for implementation into one partners' software.

     In accordance with SFAS 131, we are continuing to report operating  results
by business  unit.  The figures for all  divisions are based on an allocation of
overhead  and  all  indirect  costs  in  the  following  matter:  BizPay  (70%),
Counterfeit  Cop (25%),  and MultiMedia  (5%). The Counterfeit Cop division lost
$250,893  in the  quarter on  revenues  of  $35,810.  For the six  months  ended
November 30, 2000,  the division  lost $53,576 on revenues of $779,439.  Neither
the BizPay  division nor the multimedia  division had any revenue in the quarter
ended  November 30, 2000. The  multimedia  division did partially  complete it's
first project, but we have chosen to recognize the income when paid, rather than
on a percentage of completion  basis. As of January 15, 2001, we have received a
total of $2,750 for the  project.  The  division  has  received  two  additional
projects that are partially completed as of this filing. Expenses for the BizPay
division were  $1,182,278  for the quarter,  and  $2,076,167  for the six months
ended  November  30,  2000.  The  figures  for all  divisions  are  based  on an
allocation of overhead and all indirect  costs in the following  matter:  BizPay
70%, Counterfeit Cop 25%, and MultiMedia 5%.

     We have been involved in material  litigation  with holders (the "Debenture
Holders") of our 6% Convertible  Debentures Due May 29, 2003 (the "Debentures").
In 1998, the Debenture Holders filed a lawsuit against us based upon our failure
to honor  their  requests  to  convert  the  Debentures  to  common  stock  (the
"Debenture  Litigation").  In January  1999,  the  Debenture  Holders  and other
plaintiffs  (together,  the "Plaintiffs")  filed related lawsuits against us and

                                       6
<PAGE>
certain of our former  officers,  and  others,  to recover  damages  for alleged
intentional and calculated  defamation (the "Defamation  Litigation").  On April
11, 2000,  we entered into a definitive  Settlement  Agreement  and  Conditional
Release  with  the  Plaintiffs  to  settle  the  Debenture  Litigation  and  the
Defamation  Litigation.  Provided  that  we  honor  our  obligations  under  the
Settlement  Agreement and the Debentures,  which we intend to do, the settlement
will fully and  finally  resolve the  Debenture  Litigation  and the  Defamation
Litigation. Under the Settlement Agreement, we have agreed to honor the terms of
the Debentures  (and the related common stock purchase  warrants) and to convert
the principal and accrued  interest on the  Debentures  into our common stock as
the  Debenture  Holders  request  such  conversion  and as  permitted  under the
Debentures.  As of  November  30,  2000,  and January  10,  2000,  approximately
$2,843,000 and $2,938,000 respectively in principal amount of the Debentures has
been converted into shares of our common stock in partial  implementation of the
settlement. In addition, we have agreed to pay (in common stock, to be issued as
the  Debentures  are  converted) an additional  $350,000 in liquidated  damages,
which  amount was accrued in the third  quarter of the year ending May 31, 2000.
We  have  agreed  to  perform  additional  non-monetary  obligations  under  the
Settlement   Agreement  which,  while  they  represent  material  terms  of  the
Settlement  Agreement and Conditional  Release,  we believe we can  successfully
perform without a material adverse financial impact.

     We are involved in litigation  with a former officer and director  relating
to his  claims  for  indemnification  and  reimbursement  of legal  expenses  in
connection  with the  Defamation  Litigation,  and for  breach of an  employment
agreement with respect to stock  options.  The former  executive  seeks damages,
including  substantial exemplary and punitive damages, and an order requiring us
to  honor  stock  options.  Although  we  believe  that  the  settlement  of the
Defamation  Litigation  mitigates  potential  damages  in this  litigation,  the
outcome of this litigation,  and its potential financial impact on us, cannot be
estimated fully at this time.  However, at the present time, we believe that the
claims for  exemplary  and punitive  damages  relating to both the indemnity and
stock option claims are wholly without merit.

     We have been involved in litigation  with a former customer who has alleged
that we breached an agreement  to provide  software  conversion  services and to
test its software for the ability to function in the year 2000 and beyond. While
we believe that the outcome of any  litigation  would have been  favorable,  our
analysis indicated the potential cost of trying the case would have been greater
than the settlement offer on the table. We settled the case during December 2000
for $125,000 to be paid over the next fifteen months.

     In preparation  for our annual  meeting,  which was held December 11, 2000,
the Company  asked its  shareholders  to approve an  increase  in the  Company's
authorized shares from 40 million to 69 million.  This increase was necessary to
assure  that  the  Company  would  be  able to meet  all  existing  obligations,
including  the  conversion  of the debenture  bonds.  Additionally,  the Company
planned  to sell a  specific  number of shares in a private  placement  to raise
operating  capital.  By a vote  of  19,971,371  to  2,688,206  the  shareholders
approved the proposal.

                                       7
<PAGE>
MATERIAL CHANGES IN RESULTS OF OPERATIONS

     NET  LOSSES.  For the three and six months  ended  November  30,  2000,  we
incurred net losses of $1,487,911  and  $2,351,965,  compared with net losses of
$1,000,851  and $2,416,253 for the three and six months ended November 30, 1999,
an increase and decrease of approximately $487,060 and 64,288. An explanation of
these losses is set forth below.

     REVENUE.  For the three and six months  ended  November  30,  2000,  we had
revenues  of $35,810 and  779,439,  compared to $65,435 and 183,303 for the same
quarter in the  previous  year.  The  increase  in revenue  for the year to date
reflects growth in revenues from sales of the  COUNTERFEIT COP product.  Revenue
for the quarter was not helped by any significant Counterfeit Cop sales from our
master  distributors.  Our two salespeople spent most of the quarter on the road
training  our  master  distributors  and  their  alliance  partners,   with  the
expectation of large sales growth in the following quarters.

     COST OF SALES. For the quarter ended November 30, 2000, the primary cost of
sales expense is the cost of obtaining  COUNTERFEIT COP units from our supplier.
These costs represent approximately 35% of related revenue.

     SOFTWARE  RESEARCH AND DEVELOPMENT  EXPENSES.  For the three and six months
ended November 30, 2000, software development expenses were $415,227 and 710,767
compared with $190,206 and 315,381 for the comparable prior period. The increase
in software  development expenses represents the large investment we made in the
development of the BizPay product.  We have added staff with specialized  skills
where  appropriate,  and have used consultants as needed.  As we proceed through
beta testing,  the initial  product roll out, and the  development of subsequent
phases of  BizPay,  including  the  wireless  applications,  we do not  expect a
significant  decrease  in  software  development  expenses.  We  intend to begin
capitalizing  certain  software  development  costs  when  proprietary  software
products have reached technological feasibility.

     SELLING,  GENERAL  AND  ADMINISTRATIVE   EXPENSES.   Selling,  general  and
administrative expenses were $778,650 and 1,691,948 for the three and six months
ended November 30, 2000,  compared with $598,325 and 1,382,260 for the identical
quarter  in  the  previous   year.   The   increase  in  selling,   general  and
administrative  expenses is primarily attributable to the creation of the BizPay
business  line,  and the training of our  Counterfeit  Cop master  distributors,
alliance partners and salespeople. Additionally, legal and professional expenses
for the quarter were higher than  anticipated due to the settlement of the prior
customer's lawsuit and the expense of filing an SB-2 registration statement.

     INTEREST  EXPENSE.  For the three and six months  ended  November 30, 2000,
interest  expense was $276,119 and 434,105,  compared  with $136,113 and 233,127
for the same quarter in the previous  year, an increase of $140,006 and 200,978.
The  increase in  interest  expense is  primarily  attributable  to  accelerated
amortization of deferred financing costs due to conversion of the debentures.

                                       8
<PAGE>
     DEPRECIATION AND AMORTIZATION  EXPENSE.  For the three and six months ended
November 30, 2000, depreciation and amortization expense was $40,968 and 82,829,
compared with $65,992 and 125,002 for the previous year. The decrease  indicates
that there has been no major growth in  depreciable  items,  primarily  due to a
shortage of operating  capital.  As we have retired some depreciable  assets, we
have primarily replaced them with leased assets.  Additionally,  the development
of the BizPay products has required an investment in hardware and software.  For
the most part,  the necessary  equipment  has been leased at  prevailing  market
rates.

MATERIAL CHANGES IN FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

     The  Company  has  continued  to suffer  material  operating  losses and is
experiencing difficulties meeting its current obligations.  Although revenue has
increased substantially, current revenue levels are still inadequate to meet all
of the company's  obligations.  The Company is  attempting  to raise  sufficient
equity capital to meet its current obligations and to implement its new business
plan. However, the Company has experienced  difficulty in doing so and there can
be no assurance  that it will be successful in raising  capital or  implementing
its new business plan.

     The Company has utilized  significant  resources  in software  development,
research and marketing  efforts.  The investment in the BizPay  technology alone
during the quarter ended  November 30, 2000 was over  $1,180,000.  Those efforts
must continue in order for the Company to be successful in the implementation of
its new strategic direction.  The Company will require additional capital,  most
likely from private  placement  equity,  in order to meet its obligations and to
implement its new strategic direction.

     As of November  30,  2000,  the Company had no cash on hand  compared  with
approximately  $2,900 at August 31,  2000.  The  Company  had a working  capital
deficit of approximately  $2,533,000 at August 31, 2000, compared with a working
capital  deficit of  approximately  $2,298,000  at May 31, 2000,  an increase in
working  capital  deficit of  approximately  $235,000.  The  increase in working
capital deficit is primarily attributable to the operating loss sustained during
the quarter,  which was somewhat  mitigated by the conversion of the debentures.
The Company had convertible debentures outstanding of $1,259,000 and $657,000 at
August 31 and at November 30, 2000.

                                       9
<PAGE>
     Through the  quarter,  the Company  continued  to raise  operating  capital
through the sale of its common stock, and through borrowings and other financing
activities.  During the six months  ended  November  30,  2000,  the Company has
realized over  $860,000 in proceeds from the sale of it's common stock,  and has
borrowed money from one director and one member of  management,  Those loans are
not collateralized,  and total over $100,000.  If the Company continues to incur
significant  losses,  the Company's  liquidity could be materially and adversely
affected.  The  Company  does not  currently  have any  established  bank credit
facility,  and there can be no assurance that the Company will be able to obtain
the  additional  capital in the form of debt or equity  financing  necessary  to
continue its operations if no significant  sales are realized.  The Company does
not intend to require material capital  expenditures in the short term. However,
as discussed  above,  the Company will require cash to continue to implement its
strategic direction.

IMPACT OF INFLATION

     Increases in the  inflation  rate are not expected to effect the  Company's
operating  expenses.  Although  the  Company  has no  current  plans  to  borrow
additional  funds, if it were to do so at variable  interest rates, any increase
in interest rates would increase the Company's borrowed funds.

SEASONALITY

     Our operations are not affected by seasonal fluctuations, although our cash
flows may at times be affected by  fluctuations  in the timing of cash  receipts
from large  contracts.  Management  believes that the cash-flow of the two major
product  lines in our new  strategic  direction  will not be  impacted  by large
purchases or seasonal factors.

                           PART II. OTHER INFORMATION

ITEM 5. OTHER INFORMATION.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

     (a)  Exhibits.

     The list of Exhibits  which are filed with this report or  incorporated  by
reference  herein is set forth in the Exhibit  Index that appears  following the
signature page, which Exhibit Index is incorporated herein by this reference.

     (b)  Reports on Form 8-K.

     The  Company  filed form 8-K on  12/30/98,  which  reported a legal  action
against the  Company,  on  December 3, 1998,  for  specific  performance  of the
provisions  of the  Debentures  which  permit the  holders  to convert  the debt
evidenced  by the  debentures  into shares of the  Company's  common  stock.  On
December  28, 1998,  the Company  filed an answer in that action  denying  that,
under the pertinent  circumstances,  the Company is obligated to effect any such
conversion.  The Company also filed a counterclaim  against the holders, and new
claims against certain agents of the holders, in the same action,  alleging that
the holders and the agents made material  misrepresentations  in connection with
the purchase and sale of the  Debentures  and made  unlawful  short sales of the
Company's common stock. The Company filed form 8-K on March 22, 2000,  detailing
the settlement term sheet agreed to with the debenture holders.

                                       10
<PAGE>
                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                        CONSYGEN, INC.


Date: January 12, 2000                  By: /s/ A. Lewis Burridge
                                            ------------------------------------
                                            A. Lewis Burridge, President
                                            (Principal Executive Officer)

                                       11
<PAGE>
                                 EXHIBIT INDEX

2         Plan of Acquisition  between the Registrant  and the  stockholders  of
          ConSyGen,  Inc., an Arizona corporation,  dated August 28, 1996, filed
          as  Exhibit  2 to the  Registrant's  Current  Report on Form 8-K dated
          September 5, 1996 and incorporated herein by reference.
3.1       Articles of Incorporation of the Registrant, as amended. (1)
3.2       Amended and Restated By-Laws of the Registrant. (4)
4.1       Specimen  common  stock  certificate,  filed  as  Exhibit  4.B  to the
          Registrant's  Registration Statement on Form S-18, File No. 33-22900 -
          FW, and incorporated herein by reference.
4.2       Form of Common Stock Purchase Warrant used in connection with issuance
          of  warrants  to  purchase an  aggregate  of  1,000,000  shares of the
          Registrant's Common Stock, $.003 par value. (2)
4.3       Subscription  Agreement  used in connection  with the Rule 506 sale of
          Convertible Debentures in the aggregate principal amount of $3,500,000
          (including form of Convertible Debenture, form of Warrant, and form of
          Registration  Rights  Agreement,  attached  as  Exhibits  A,  B and D,
          respectively, to the Subscription Agreement). (6)
4.4       Form of Common  Stock  Purchase  Warrant to purchase an  aggregate  of
          10,000 shares issued in partial payment of finders' fees in connection
          with sale of Convertible  Debentures in aggregate  principal amount of
          $3,500,000. (6)
4.5       Form of  Subscription  Agreement used in connection with Rule 506 sale
          of 120,000 shares for gross proceeds of $1,080,000. (1)
4.6       Form of  Subscription  Agreement used in connection with Rule 506 sale
          of 152,000 shares for gross proceeds of $882,500. (1)
4.7       Form of Common  Stock  Purchase  Warrant to  purchase  200,000  shares
          issued to consultant, Howard R. Baer, on August 1, 1997. (1)
4.8       Form of Common  Stock  Purchase  Warrant to  purchase  100,000  shares
          issued to Howard R. Baer's designee, Kevin C. Baer, on August 1, 1997.
          (1)
4.9       Subscription  Agreement  used in  connection  with  Rule  506  sale of
          900,000 shares for gross proceeds of $5,276,250. (3)
4.10      Form of  Subscription  Agreement  used in connection  with issuance of
          30,747 shares in payment of  indebtedness  in the aggregate  amount of
          $250,575. (3)
4.11      Common Stock Purchase  Warrant to purchase  100,000 shares issued to a
          consultant's designee, Irvington International Limited, as of November
          10, 1997. (3)
4.12      Agreement  dated as of July 17, 1998 between the Registrant and Tom S.
          Dreaper  relating  to  employment  and grant of  options  to  purchase
          1,000,000 shares of common stock of the Registrant. (6)
4.13      Agreement  entitled  "Transfer of Complete Rights in Software  Program
          between ConSyGen, Inc. and F&M Investments,  L.L.C.", filed as Exhibit
          4.13 to the Registrant's Current Report on Form 8-K dated July 2, 1999
          and incorporated herein by reference.
4.14      Amendment   dated  August  13,  1998,  to  6%  Convertible   Debenture
          Subscription Agreement and related Registration Rights Agreement dated
          May 29, 1998, filed as Exhibit 4.13 to the  Registrant's  Registration
          Statement on Form S-3, File No. 333-61869,  and incorporated herein by
          reference.
4.15      Form  of  Subscription  Agreement  used  in  connection  with  private
          placement  of  4,498,000  units,   consisting  of  one  share  of  the
          Registrant's  common  stock and a  warrant  to  purchase  one share of
          common stock, for total cash consideration of $1,124,500.
<PAGE>
4.16      Form of Common Stock Purchase Warrant used in connection with issuance
          of  warrants  to  purchase  an  aggregate   of  4,498,000   shares  of
          Registrant's Common Stock, $0.003 par value.
4.17      Option  Agreement  for  1,000,000  shares of the  Registrant's  common
          stock, dated April 17, 2000, issued to consultant, Howard R. Baer.
10.7      Registrant's 1996 Non-Qualified Stock Option Plan. (2)
10.8      Registrant's  Second  Amended and Restated  1997  Non-Qualified  Stock
          Option Plan. (8)
10.9      Consulting  Agreement  between the Registrant and M.H. Meyerson & Co.,
          Inc. dated August 19, 1996. (5)
10.10     Form of  Indemnification  Contract  between  the  Registrant  and each
          executive officer and director of the Registrant. (3)
10.11     Agreement  between the Registrant  and Carriage  House Capital,  Inc.,
          effective as of September 1, 1997, terminating all existing agreements
          between the  Registrant  and Carriage  House  Capital,  Inc.,  and its
          affiliates. (3)
10.12     Registrant's  Form of Settlement Term Sheet between the Registrant and
          the Debenture Parties (Thomson Kernaghan, et al). (7)
10.13     Settlement  Agreement and  Conditional  Release between the Registrant
          and the Debenture Parties dated April 20, 2000. (9)
10.14     Agreement between the Registrant and Saviar and Spaeth,  dated January
          11, 2000.
16        Letter dated  September  24, 1998 from  Wolinetz,  Gottlieb & Lafazan,
          P.C. to the Securities and Exchange Commission, filed as Exhibit 16 to
          the  Registrant's  Current Report on Form 8-K dated September 22, 1998
          and incorporated herein by reference.
21        List of Subsidiaries of the Registrant. (9)
99.1      Registrant's 2000 Combination Stock Option Plan. (10)

-----------
*    Filed herewith.
(1)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Quarterly  Report on Form 10-Q for the quarter  ended August 31, 1997,  and
     incorporated herein by reference.
(2)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Quarterly  Report on Form 10-Q for the quarter  ended August 31, 1996,  and
     incorporated herein by reference.
(3)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Registration  Statement on Form S-1, File No.  333-40649,  and incorporated
     herein by reference.
(4)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Quarterly  Report on Form 10-Q for the quarter ended February 28, 1998, and
     incorporated herein by reference.
(5)  Filed as Exhibit No. 10.10 to the  Registrant's  Annual Report on Form 10-K
     for the year ended May 31, 1997, and incorporated herein by reference.
(6)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Annual  Report  on  Form  10-K  for  the  year  ended  May  31,  1998,  and
     incorporated herein by reference.
(7)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Annual Report on Form 8-K dated March 22, 2000, and incorporated  herein by
     reference.
(8)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Quarterly  Report on Form 10-Q for the quarter  ended August 31, 1998,  and
     incorporated herein by reference.
(9)  Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Annual  Report  on Form  10-KSB  for the  year  ended  May  31,  2000,  and
     incorporated herein by reference.
(10) Filed as an Exhibit,  with the same  Exhibit  number,  to the  Registrant's
     Registration  Statement on Form S-8,  dated May 4, 2000,  and  incorporated
     herein by reference.

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission